Following the likes of Kailera & Metsera last year, a new obesity biotech has emerged with clinical-stage assets. London & San Fran biotech Verdiva begins with $411 million, an oral GLP-1 set for Phase 2 this year and preclinical amylin prospects.

The team mainly derives from GSK-acquired Aiolos